Concentrate for the preparation of infusion emulsion
Vitalipid N Infant is a medicine containing fat-soluble vitamins, administered intravenously to infants and children when oral feeding is not possible. Vitamins are organic substances required in small amounts for the proper functioning of the body. Vitalipid N Infant is indicated for use as a component of clinical parenteral nutrition, together with proteins, fats, carbohydrates, salts, and other vitamins.
Do not use the medicine:
Tell the doctor if the child is taking any medicines containing vitamin A. The doctor may order regular blood tests to check the patient's health.
Tell the doctor or pharmacist about all medicines the child is currently taking or has recently taken, as well as any medicines the child will be taking. Inform the doctor if the patient is taking medicines that prevent blood clotting (anticoagulants) or medicines containing vitamin A.
Do not use in case of known hypersensitivity to peanuts or soy. Cross-allergic reactions have been observed between soy and peanuts.
The medicine contains purified egg yolk phospholipids, which may rarely cause allergic reactions.
The medicine contains less than 1 mmol (23 mg) of sodium per 10 ml, which means the medicine is considered "sodium-free".
Vitalipid N Infant is administered by intravenous infusion (drip). The dosage for each patient is determined by the doctor.
The usual daily dose of Vitalipid N Infant is 4 ml per kilogram of body weight.
The usual daily dose of Vitalipid N Infant is 10 ml.
Vitalipid N Adult is recommended.
The doctor or nurse will monitor the patient's health during the infusion, so there is little likelihood of administering a higher dose than recommended. However, if the patient thinks they have received a higher dose of Vitalipid N Infant than recommended, they should immediately inform the doctor or nurse. Symptoms of overdose may include headache, nausea, vomiting, and drowsiness. In case of any further doubts about the use of this medicine, consult a doctor or nurse.
No side effects have been reported with the use of Vitalipid N Infant.
If any side effects occur, including any side effects not listed in this leaflet, tell the doctor, pharmacist, or nurse. Side effects can be reported directly to the Department of Monitoring of Adverse Reactions to Medicinal Products of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, tel.: +48 22 49 21 301, fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl. Reporting side effects can help gather more information on the safety of the medicine.
The doctor or nurse is responsible for ensuring proper storage, use, and disposal of Vitalipid N Infant. Store in a temperature below 25°C. Protect from light. Do not freeze. Do not use this medicine after the expiry date stated on the packaging. The expiry date refers to the last day of the month stated. Unused medicine is not suitable for further use. Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
1 ml contains:
retinyl palmitate
135.3 μg
(corresponding to retinol)
(69 μg)
phylloquinone
20 μg
ergocalciferol
1.0 μg
all-rac-α-tocopherol
0.64 mg
which corresponds to:
vitamin A
69 μg
(230 IU)
vitamin D
1.0 μg
(40 IU)
vitamin E
0.64 mg
(0.7 IU)
vitamin K
20 μg
10 ml contains:
retinyl palmitate
1353 μg
(corresponding to retinol)
(690 μg)
phylloquinone
200 μg
ergocalciferol
10 μg
all-rac-α-tocopherol
6.4 mg
which corresponds to:
vitamin A
690 μg
(2300 IU)
vitamin D
10 μg
(400 IU)
vitamin E
6.4 mg
(7 IU)
vitamin K
200 μg
Osmolality: approximately 300 mOsm/kg water, pH: approximately 8.
Vitalipid N Infant is a sterile concentrate for the preparation of infusion emulsion of the oil-in-water type, containing fat-soluble vitamins in the oil phase. Each ampoule contains 10 ml of the concentrate for infusion emulsion. Vitalipid N Infant is available in glass ampoules (type I glass), packaged in 10 pieces in a cardboard box. For more detailed information, please contact the marketing authorization holder or the parallel importer.
Fresenius Kabi España S.A.U
C/Marina 16-18, 08005 Barcelona, Spain
Fresenius Kabi AB
Rapsgatan 7, SE-751 74 Uppsala, Sweden
InPharm Sp. z o.o.
ul. Strumykowa 28/11, 03-138 Warsaw
InPharm Sp. z o.o. Services sp. k.
ul. Chełmżyńska 249, 04-458 Warsaw
Marketing authorization number in Spain, the country of export:680397.4
Parallel import authorization number:32/20
[Information about the trademark]
Vitalipid N Infant contains purified soybean oil and purified egg yolk phospholipids, which may rarely cause allergic reactions. Cross-allergic reactions have been observed between soy and peanuts. Vitalipid N Infant must not be used in an undiluted form.
Dosage
The recommended dose to meet the needs of preterm infants and newborns with low birth weight (up to 2.5 kg) is 4 ml/kg body weight/day.
The recommended dose to meet the needs of newborns and children up to 11 years old and with a body weight over 2.5 kg is 10 ml/day.
Administration
Instructions for diluting the medicine before administration, see section: Preparation of the medicine for use.
Overdose of fat-soluble vitamins may cause toxicity symptoms, but there are no data on toxicity during the use of Vitalipid N Infant in the recommended doses. After a single overdose of fat-soluble vitamins, no side effects should occur. No specific treatment is necessary. After prolonged infusion of excessive doses of vitamin D, elevated levels of vitamin D metabolites in serum may occur, which may cause osteopenia. Infusion of vitamin K in a colloidal aqueous solution at a rate greater than recommended may cause flushing, bronchospasm, tachycardia, and hypotension. Such reactions have not been reported after infusion of Vitalipid N Infant.
Pharmaceutical compatibility and instructions for preparation of the medicine for use
During mixing with other medicines, aseptic principles must be observed. No more than 10 ml (1 ampoule) of Vitalipid N Infant should be added to Intralipid 10% or Intralipid 20%. To ensure homogeneity of the mixture, the container should be turned several times immediately before infusion. Vitalipid N Infant can be dissolved in SOLUVIT N and used in children with a body weight over 10 kg. The mixture resulting from dissolving SOLUVIT N in Vitalipid N Infant is not recommended for use in children with a body weight below 10 kg due to differences in dosing. Storage after mixing: addition of Vitalipid N Infant to Intralipid 10% or Intralipid 20% should be performed within 1 hour before the start of infusion, and the infusion should be completed within 24 hours of preparation of the mixture to avoid microbiological contamination. Unused contents of opened bottles/vials/ampoules should be destroyed; they should not be stored for further use. Data on stability and pharmaceutical compatibility with medicines used for parenteral nutrition are available on request from the marketing authorization holder.
Do not mix the medicine with other medicines, except those listed in the section: Preparation of the medicine for use.
Store in a temperature below 25°C. Protect from light. Do not freeze.
Any unused medicine or waste material should be disposed of in accordance with local requirements.
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.